Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 14/20 | 0.44 |
| ▸ | SRC | P12931 | 10/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1242544 | 0.84 | DAO (0.59) | DAOKDM4EGLAGAA | |
| SCHEMBL24702448 | 0.82 | DAO (0.71) | DAOABL1SRCKDM4E | |
| SCHEMBL1244760 | 0.80 | DAO (1.00) | DAOKDM4E | |
| SCHEMBL21480306 | 0.79 | KMT2A (0.51) | DAOCYP1A2MAPK1KDM4E | |
| SCHEMBL23146188 | 0.79 | DAO (0.71) | DAOKDM4E | |
| SCHEMBL23146424 | 0.79 | DAO (0.71) | DAOKDM4E | |
| SCHEMBL7681873 | 0.77 | DAO (0.66) | DAOCYP1A2ABL1SRCMAPK1 | |
| SCHEMBL21480281 | 0.77 | RAB9A (0.59) | DAOABL1 | |
| SCHEMBL21677369 | 0.76 | DAO (0.67) | DAOMAPK1KDM4EGAA | |
| SCHEMBL21480414 | 0.76 | DYRK1A (0.49) | DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12168012-B2 | NLRP3 inflammasome inhibitors | NOVARTIS AG (CH) | 2024-12-17 | — | — | US | disclosed |
| EP-3827008-B1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2024-07-31 | — | — | EP | disclosed |
| US-20210308140-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2021-10-07 | — | — | US | disclosed |
| EP-3827008-A1 | NLRP3 INFLAMMASOME INHIBITORS | Novartis AG (CH) | 2021-06-02 | — | — | EP | disclosed |
| WO-2020021447-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2020-01-30 | — | — | WO | disclosed |
| US-20130196960-A1 | Cannabinoid Receptor Agonists | IRONWOOD PHARMACEUTICALS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130196960-A1 | Cannabinoid Receptor Agonists | IRONWOOD PHARMACEUTICALS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130196960-A1 | Cannabinoid Receptor Agonists | IRONWOOD PHARMACEUTICALS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| WO-2011100324-A1 | CANNABINOID RECEPTOR AGONISTS | Ironwood Pharmaceuticals Inc. (US) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12168012-B2 | NLRP3 inflammasome inhibitors | NLRP3, NLRP1, NOD1 | DAO 4735/4885CYP1A2 678/4885ABL1 4042/4885 |
| US-20130196960-A1 | Cannabinoid Receptor Agonists | CNR2, CNR1, GPR18 | DAO 3817/4885CYP1A2 1696/4885ABL1 881/4885 |
| US-20210308140-A1 | NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, NOD1 | DAO 4720/4885CYP1A2 765/4885ABL1 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.